Intest Res.  2014 Apr;12(2):146-152. 10.5217/ir.2014.12.2.146.

Does Diabetes Mellitus Influence Standardized Uptake Values of Fluorodeoxyglucose Positron Emission Tomography in Colorectal Cancer?

• Oh DY
• Kim JW
• Koh SJ
• Kim M
• Park JH
• Cho SY
• Kim BG
• Lee KL
• Im JP

• KMID: 2284900
• DOI: http://doi.org/10.5217/ir.2014.12.2.146

Abstract

BACKGROUND/AIMS
Hyperglycemia is associated with decreased 2-18[F]fluoro-2-deoxy-D-glucose (FDG) uptake by tumors assessed by positron emission tomography (PET). In this retrospective study we investigated a comparison of standardized uptake values (SUVs) in patients with primary colorectal cancers who either had diabetes mellitus (DM) or were otherwise healthy.
METHODS
The medical records of 397 patients who were diagnosed with colorectal cancer and underwent PET-CT between January 2006 and December 2012 were analyzed. Eighty patients with DM and 317 patients without DM were included. Clinical characteristics were reviewed and maximal standardized uptake values (SUVmax) were calculated in the primary colorectal lesions.
RESULTS
There was no significant difference between tumor SUVmax in DM patients (10.60+/-5.78) and those without DM (10.92+/-5.44). In addition, no significant difference was detected between tumor SUVmax in DM patients with glycated hemoglobin (HbA1c) levels <8% (10.34+/-5.17) and those with HbA1c levels > or =8% (10.61+/-7.27). The maximum size of the primary colorectal tumor was associated with SUVmax in a linear regression analysis.
CONCLUSION
The results of this study showed that DM did not influence FDG uptake values in colorectal cancer patients regardless of glucose levels.

Keyword

Diabetes mellitus; Positron emission tomography; Colorectal neoplasms

MeSH Terms

Colorectal Neoplasms*
Diabetes Mellitus*
Glucose
Hemoglobin A, Glycosylated
Humans
Hyperglycemia
Linear Models
Medical Records
Positron-Emission Tomography*
Retrospective Studies
Glucose

Figure

• 

  Fig. 1 Comparison of maximal standardized uptake values (SUVmax) in colorectal cancer patients with or without diabetes mellitus (DM) (P=0.642).

• 

  Fig. 2 Comparison of maximal standardized uptake values (SUVmax) in colorectal cancer patients with diabetes mellitus (DM) according to control of glucose (P=0.860). HbA1c, glycated hemoglobin.

• 

  Fig. 3 Distribution between maximal standardized uptake values (SUVmax) and glucose in diabetes mellitus (DM) patients. The correlation coefficient(r) was -0.051.

• 

  Fig. 4 Difference of maximal standardized uptake values (SUVmax) in diabetes mellitus (DM) patients (n=80) according to treatment (P=0.239). OHA, oral hypoglycemic agent.

Reference

1. Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat. 2012; 44:11–24. PMID: 22500156.

2. Park SK, Park MK, Suk JH, et al. Cause-of-death trends for diabetes mellitus over 10 years. Korean Diabetes J. 2009; 33:65–72.

3. Yi BD, Bae YP, Kim BG, et al. The association between type 2 diabetes mellitus and colorectal cancer. Endocrinol Metab. 2011; 26:126–132.

4. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97:1679–1687. PMID: 16288121.

5. Endo K, Oriuchi N, Higuchi T, et al. PET and PET/CT using ¹⁸F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol. 2006; 11:286–296. PMID: 16937302.

6. Lee JC, Hartnett GF, Hughes BG, Ravi Kumar AS. The segmental distribution and clinical significance of colorectal fluorodeoxyglucose uptake incidentally detected on PET-CT. Nucl Med Commun. 2009; 30:333–337. PMID: 19262416.

7. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer--a PET study. J Nucl Med. 1993; 34:1–6. PMID: 8418248.

8. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998; 39:1030–1033. PMID: 9627339.

9. Langen KJ, Braun U, Rota Kops E, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med. 1993; 34:355–359. PMID: 8441023.

10. Haley M, Konski A, Li T, et al. Influence of diabetes on the interpretation of PET scans in patients with esophageal cancer. Gastrointest Cancer Res. 2009; 3:149–152. PMID: 19742140.

11. Gorenberg M, Hallett WA, O'Doherty MJ. Does diabetes affect [¹⁸F]FDG standardised uptake values in lung cancer? Eur J Nucl Med Mol Imaging. 2002; 29:1324–1327. PMID: 12271414.

12. Chang YC, Yen TC, Ng KK, et al. Does diabetes mellitus influence the efficacy of FDG-PET in the diagnosis of cervical cancer? Eur J Nucl Med Mol Imaging. 2005; 32:647–652. PMID: 15703931.

13. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med. 1999; 40:556–565. PMID: 10210213.

14. Marom EM, Aloia TA, Moore MB, et al. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer. 2001; 33:99–107. PMID: 11551404.

15. Kim SY, Lee SY, Lim HK, et al. Relationship between positron emission tomography uptake and macroscopic findings of colorectal cancer. Intest Res. 2012; 10:168–175.

16. Zou MH, Kirkpatrick SS, Davis BJ, et al. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem. 2004; 279:43940–43951. PMID: 15265871.

17. Walker J, Jijon HB, Diaz H, Salehi P, Churchill T, Madsen KL. 5-aminoimidazole-4-carboxamide riboside (AICAR) enhances GLUT2-dependent jejunal glucose transport: a possible role for AMPK. Biochem J. 2005; 385:485–491. PMID: 15367103.

18. Gontier E, Fourme E, Wartski M, et al. High and typical ¹⁸F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging. 2008; 35:95–99. PMID: 17786437.

19. Bybel B, Greenberg ID, Paterson J, Ducharme J, Leslie WD. Increased F-18 FDG intestinal uptake in diabetic patients on metformin: a matched case-control analysis. Clin Nucl Med. 2011; 36:452–456. PMID: 21552023.

20. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point ¹⁸F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001; 42:1412–1417. PMID: 11535734.

21. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA. A PET study of ¹⁸FDG uptake in soft tissue masses. Eur J Nucl Med. 1999; 26:22–30. PMID: 9933658.

22. Matthies A, Hickeson M, Cuchiara A, Alavi A. Dual time point ¹⁸F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med. 2002; 43:871–875. PMID: 12097455.